tbuckley/cabot-search huggingface dataset:
TCT-10 Clinical outcomes following “full-plastic jacket” bioresorbable scaffold implantation
Authors: Hiroyoshi Kawamoto, Azeem Latib, Neil Ruparelia, Akihito Tanaka, Alessandro Sticchi, Francesco Giannini, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
The clonality of immunoglobulin repertoire in prostate cancer-infiltrating B cells.
Authors: Martin Trepel, Phillip R. Stahl, Carsten Bokemeyer, Anna Flammiger
Journal: Journal of Clinical Oncology (2012)

e15168 Background: There is emerging evidence that inflammation plays a role in prostate carcinogenesis. To better understand the cellular biology of the immune response in prostate cancer, we investigated the immunoglobulin (Ig) repertoire of tumor-infiltrating B cells. Methods: The Ig heavy chain variable region (V H ) usage reflects the antigenic experience of tumor-infiltrating B cells and may help to identify potential therapeutic targets. We analyzed IgM-V H and IgG-V H transcripts of tumor-infiltrating B cells in four tumor samples of localized prostate cancer. Immunohistochemical staining revealed groups of CD20+ B cells surrounding neoplastic prostate glands. To exclude PCR amplification bias, two cDNA librarys were prepared from separate tissue sections of each tumor. IgM-V H and IgG-V H transcripts were amplified by RT-PCR from each cDNA library, cloned and sequenced. Results: Sequencing of a total of 80 IgM-V H and 80 IgG-V H PCR products (10 IgM-V H and 10 IgG-V H PCR products from each cDNA library) revealed an oligoclonal Ig repertoire in 3 of 4 and evidence of antigen experience of B cells in 4 of 4 prostate cancer samples. IgM and IgG B cell clones, defined by the same complementarity-determining region 3 (CDR3) and detection in two separate cDNA librarys, were widely distributed in the prostate. Prostate cancer-infiltrating B cells showed somatic hypermutation, Ig class switch and insertions or deletions indicating antigen experience. Conclusions: Clonally related B cells are widely distributed in the neoplastic prostate gland suggesting the recognition of a limited number of epitopes. Future studies will identify the antigens eliciting this immune response.
TCT-342 Impact of Daily Glucose Fluctuation on Vessel Healing after 2nd Generation Drug-eluting Stent Implantation Assessed by Continuous Glucose Monitoring and Optical Coherence Tomography
Authors: Masaru Kuroda, Toshiro Shinke, Hiromasa Otake, Tomofumi Takaya, Daiji Kashiwagi, Yuto Shinkura, Natsuko Tahara, Hiroto Kinutani, Hachidai Takahashi, Daisuke Terashita, Kenzo Uzu, Koji Kuroda, Yoshinori Nagasawa, Yushi Hirota, Kazuhiko Sakaguchi, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2015)
Investigations of oral uracil and tegafur(UFT)-based adjuvant chemotherapy in patients with colon cancer
Authors: S. Noshima
Journal: Journal of Clinical Oncology (2006)

13535 Background: Surgical resection plays a major role in the treatment of colon cancers. However, surgical resection alone has limitation in its use and it is necessary to administer adjuvant therapy and it would be important to define clinical significance of adjuvant chemotherapy. Methods: A total of 95 patients diagnosed with colon carcinoma were randomly assigned to one of two groups, i.e., treatment-group or non-treatment group. UFT (400 mg/day) was administered daily to 40 patients (treatment-group), one week before surgery. 55 patients (non-treatment group) received no medication before undergoing surgery. In the present study, we have investigated how adjuvant chemotherapy inhibited proliferation of colon cancer cells in vivo through monitoring cell proliferative activities (using MIB-1 antibody), expression of abnormal p53 protein and apoptosis-assays. Two groups were subjected to analyses of these study parameters. Results: Effects of preoperative administration of UFT on cellular proliferative activities: MIB-1-positive rates were 21.21 ± 2.89 (%) for treatment group and 39.02 ± 2.27 (%) for non-treatment group, and there was significant difference in MIB-1-positive-rates between the two groups (P&lt;0.0001). Effects of preoperative administration of UFT on mutated p53 protein expression: The incidence of mutated p53 protein was 20.27 ± 4.28 (%) for treatment group and 49.06 ± 4.46 (%) for non-treatment group, and there was significant difference in the incidence of mutated p53 protein expression between the two groups (P&lt;0.0001). Effects of preoperative administration of UFT on apoptosis: Apo.I. was 1.24 ± 0.20 (%) for treatment group and 0.49 ± 0.06 (%) for non-treatment group, and there was significant difference in Apo.I. between the two groups (P&lt;0.001). Conclusions: Taken together, these findings indicate that UFT-based adjuvant chemotherapy is potentially useful for treatment of colon cancer patients undergoing surgical resection. No significant financial relationships to disclose.
Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)
Authors: Erming Tian, Sarah Waheed, Jeffrey Sawyer, Qing Zhang, Christoph Heuck, Madhav V. Dhodapkar, Bart Barlogie, Joshua Epstein
Journal: Blood (2013)
The Clinical Profile of <i>GBA</i>-Related Lewy Body Disorders
Authors: Cyrus P. Zabetian
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Efficacy of Hydroxyurea To Prevent Organ Damage in Young Children with Sickle Cell Anemia.
Authors: Courtney D. Thornburg, Natalia Dixon, Shelly Burgett, Nicole A. Mortier, Sherri A. Zimmerman, Melanie J. Bonner, Agustin Calatroni, Russell E. Ware
Journal: Blood (2007)
UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC).
Authors: Hélène Senellart, Emmanuelle Samalin, Antoine Adenis, David Malka, Eric Francois, Christelle De La Fouchardiere, Eveline Boucher, Astrid Lievre, Trevor Stanbury, Jaafar Bennouna
Journal: Journal of Clinical Oncology (2014)

TPS3666 Background: A previous study assessing erlotinib-cetuximab combo in chemo- refractory wt KRAS mCRC (Weickhardt AJ, et al J Clin Oncol 201;30:1505-12) has shown encouraging data (ORR=41 %, PFS=5.6 months). Afatinib is an Erb-B family blocker that irreversibly blocks signaling from all relevant Erb-B family homo and heterodimers. Methods: We conduct a randomized phase II study to determine the benefit of afatinib plus cetuximab versus cetuximab alone in patients with wtRAS metastatic CRC after oxaliplatin and irinotecan failure.Key eligibility criteria: pts with mCRC expressing wt KRAS/NRAS status; ECOG status 0 or 1; no disease progression with previous anti-EGFR targeted therapy; failure with a prior regimen containing irinotecan or oxaliplatin for metastatic disease; pts must have previously received a thymidylate inhibitor at any point for treatment of CRC; Pts are randomized 2:1 to receive oral afatinib (40 mg/qd) in combo with i.v. cetuximab (500mg/m2 q 2 weeks) or cetuximab alone (500mg/m2 q2 weeks). Dose adjustments are permitted according to the occurrence of drug related Adverse Events (AE). Pts receive treatment until PD or unacceptable AE. Pts randomized in the cetuximab arm have the opportunity to crossover to the combo arm after disease progression. The primary endpoint is the 6-month PFS rate. Secondary endpoints include ORR, median PFS, OS, safety and tolerability. Target enrolment is 75 pts. Completion of pt recruitment and data analyses are awaited. this study is promoted by UNICANCER GI. Clinical trial information: NCT01919879.
TCT-252 Prognostic Impact of Combined Dysglycemia and Hypoxic Liver Injury at Admission in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Data from INTESTELLAR cohort
Authors: Ho-Jun Jang, Tae-Hoon Kim, Jeonggeun Moon, Woong Chol Kang, Pyung Chun Oh, Jon Suh, Hyun Woo Park, Sang-Don Park, Sung Woo Kwon
Journal: Journal of the American College of Cardiology (2015)
TCT-521 Clinical outcomes after bioresorbable scaffold implantation in patients with a high prevalence of complex lesions: the Milan experience
Authors: Hiroyoshi Kawamoto, Azeem Latib, Neil Ruparelia, Akihito Tanaka, Alessandro Sticchi, Francesco Giannini, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
Acute Lymphoblastic Leukaemia Cells Carrying the t(12;21) Translocation Are Highly Sensitive to Alemtuzumab Mediated Cell Lysis.
Authors: Josee Golay, Chiara Cortiana, Giovanni Cazzaniga, Anna Salvi, Massimiliano Manganini, Orietta Spinelli, Renato Bassan, Tiziano Barbui, Andrea Biondi, Alessandro Rambaldi, Martino Introna
Journal: Blood (2005)
TCT-171 Clinical Outcomes Using Prasugrel or Ticagrelor Based On Physician Treatment Decisions In Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Comparative Results Using Propensity Analysis Of A Payer Database
Authors: Mark B. Effron, Kavita V. Nair, Cliff Molife, Stuart Y. Keller, Robert L. Page, Jason Simeone, Brian Murphy, Beth L. Nordstrom, Yajun Zhu, Patrick L. McCollam, George W. Vetrovec
Journal: Journal of the American College of Cardiology (2015)
Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone
Authors: Caroline Reynaud, Laura Ferreras, Paola Di Mauro, Casina Kan, Martine Croset, Edith Bonnelye, Floriane Pez, Clémence Thomas, Géraldine Aimond, Antoine E. Karnoub, Marie Brevet, Philippe Clézardin
Journal: Cancer Research (2016)

Lysyl oxidase (LOX) is a secreted copper-dependent amine oxidase whose primary function is to drive collagen crosslinking and extracellular matrix stiffness. LOX in colorectal cancer synergizes with hypoxia-inducible factor-1 (HIF-1) to promote tumor progression. Here we investigated whether LOX/HIF1 endows colorectal cancer cells with full competence for aggressive colonization in bone. We show that a high LOX expression in primary tumors from patients with colorectal cancer was associated with poor clinical outcome, irrespective of HIF-1 In addition, LOX was expressed by tumor cells in the bone marrow from colorectal cancer patients with bone metastases. In vivo experimental studies show that LOX overexpression in colorectal cancer cells or systemic delivery of the conditioned medium from LOX-overexpressing colorectal cancer cells promoted tumor cell dissemination in the bone marrow and enhanced osteolytic lesion formation, irrespective of HIF-1 Conversely, silencing or pharmacologic inhibition of LOX activity blocked dissemination of colorectal cancer cells in the bone marrow and tumor-driven osteolytic lesion formation. In vitro, tumor-secreted LOX supported the attachment and survival of colorectal cancer cells to and in the bone matrix, and inhibited osteoblast differentiation. LOX overexpression in colorectal cancer cells also induced a robust production of IL6. In turn, both LOX and IL6 were acting in concert to promote RANKL-dependent osteoclast differentiation, thereby creating an imbalance between bone resorption and bone formation. Collectively, our findings show that LOX supports colorectal cancer cell dissemination in the bone marrow and they reveal a novel mechanism through which LOX-driven IL6 production by colorectal cancer cells impairs bone homeostasis. Cancer Res; 77(2); 268-78. ©2016 AACR.
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus.
Authors: Ilaria Iacobucci, Marco Sazzini, Anna Ferrari, Annalisa Lonetti, Alessio Boattini, Cristina Papayannidis, Paolo Garagnani, Mariachiara Abbenante, Vilma Mantovani, Elena Marasco, Emanuela Ottaviani, Stefania Paolini, Domenico Girelli, Marco Vignetti, Fabrizio Pane, Simona Soverini, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2010)
TCT-574 The Impact of Comorbidities on Long–term PCI outcomes: Final Three year Results from the large, multi-center e-BioMatrix registry
Authors: Franz X. Kleber, Franz Eberli, Mariano Valdes, Ian Menown, Imad A. Alhaddad, David Hildick-Smith, Keith G. Oldroyd, Erifyli Kalloudi, Ashkan Yazdani, Philip Urban
Journal: Journal of the American College of Cardiology (2015)
Reversible Acute Mesenteric Ischemia
Authors: Alexandre Nuzzo, Olivier Corcos
Journal: New England Journal of Medicine (2016)

A 60-year-old man presented with abdominal pain and hypotension. He had recently had thrombosis of the superior mesenteric artery; CT showed jejunal dilatation and thinning of the bowel wall. Videos show mucosal gangrene, hemorrhage, and healing.
VIRO-TypeNed, systematic molecular surveillance of enteroviruses in the Netherlands between 2010 and 2014
Authors: Kimberley S M Benschop, Janette C Rahamat-Langendoen, Harrie G A M van der Avoort, Eric C J Claas, Suzan D Pas, Rob Schuurman, Jaco J Verweij, Katja C Wolthers, Hubert G M Niesters, Marion P G Koopmans
Journal: Eurosurveillance (2016)

VIRO-TypeNed is a collaborative molecular surveillance platform facilitated through a web-based database. Genetic data in combination with epidemiological, clinical and patient data are shared between clinical and public health laboratories, as part of the surveillance underpinning poliovirus eradication. We analysed the combination of data submitted from 2010 to 2014 to understand circulation patterns of non-polio enteroviruses (NPEV) of public health relevance. Two epidemiological patterns were observed based on VIRO-TypeNed data and classical surveillance data dating back to 1996: (i) endemic cyclic, characterised by predictable upsurges/outbreaks every two to four years, and (ii) epidemic, where rare virus types caused upsurges/outbreaks. Genetic analysis suggests continuous temporal displacement of virus lineages due to the accumulation of (silent) genetic changes. Non-synonymous changes in the antigenic B/C loop suggest antigenic diversification, which may affect population susceptibility. Infections were frequently detected at an age under three months and at an older, parenting age (25–49 years) pointing to a distinct role of immunity in the circulation patterns. Upsurges were detected in the summer and winter which can promote increased transmissibility underlying new (cyclic) upsurges and requires close monitoring. The combination of data provide a better understanding of NPEV circulation required to control and curtail upsurges and outbreaks.
Case 5-1973
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Richard A. Field, Gerald Nash
Journal: New England Journal of Medicine (1973)

Presentation of CaseA 58-year-old woman was admitted to the hospital because of anemia.The patient had diabetes of 12 years' duration, regulated on NPH insulin. Seventeen years previously an area of cystic mastitis of the right breast was excised. For many years she had suffered from migraine and was treated with multiple agents that included methysergide. Nine months before entry she was brought to the hospital because of diabetic ketoacidosis complicated by gastrointestinal blood loss, for which no source was found; the creatinine ranged from 1.8 to 0.9 mg per deciliter. One month thereafter she returned in hyperosmolar coma, . . .
TCT-264 14 Years’ Experience in a Two-step Strategy for the Treatment of Acute ST-Segment Elevation Myocardial Infarction by Percutaneous Coronary Intervention Based on a Minimalist Immediate Mechanical Intervention with Deferred Stenting. A Single Centre Study
Authors: Karl Isaaz, Antoine Gerbay, Benjamin Haber, Alexis Cerisier, Michel Lamaud, Christophe Robin, Norbert Mayaud, Jérémy Terreaux, Sarah Devidal, Laure Richard, Antoine Da Costa
Journal: Journal of the American College of Cardiology (2015)
The level of FSHR expression in the primary kidney tumors to predict the response to subsequent antiangiogenic therapy with sunitinib.
Authors: Muhammad Ahsan Siraj, Christophe Pichon, Aurelian Radu, Nicolae Ghinea
Journal: Journal of Clinical Oncology (2012)

e21138 Background: Sunitinib is an antiangiogenic receptor tyrosine kinase inhibitor used to treat advanced metastatic renal cell carcinoma and other types of cancer. Sunitinib is effective in only approx. 70% of clear cell renal cell carcinoma (CCRCC) patients, has significant adverse side effects, and no method is available to predict which patients will not respond. Our purpose was to explore the possibility of introducing an effective prediction method based on a marker of the tumor vasculature, the Follicle Stimulating Hormone Receptor (FSHR). Methods: Using immunohistochemistry on paraffin sections with anti-FSHR monoclonal antibodies we studied by photonic and fluorescence microscopy the expression of FSHR in 50 patients diagnosed with advanced metastatic CCRCC. All patients were subjected to surgery for removal of the primary tumor and were subsequently treated with sunitinib orally for ≥ 3 months with a dose of 50 mg/day for 4 weeks followed by 2 weeks off. After therapy the patients were categorized as “responsive”, “stable”, or “non-responsive” based on the RECIST guidelines. The blood vessel density and the percentage of FSHR-positive vessels were determined by immunofluorescence on sections from the primary tumors removed by surgery, prior to the sunitinib treatment. Von Willebrand factor (vWF) was used as specific endothelial marker. Results: There were no significant differences in the total density of vessels (detected with anti-vWF antibody) among the responsive, stable and non-responsive patients. The percentage of FSHR-stained vessels was on average five fold higher for the patients that responded to the treatment in comparison with the stable group and almost eight fold higher than in the non-responsive group. The percentage allowed the detection of responders with 87-100% sensitivity and specificity. Conclusions: The data suggest that FSHR expression levels in the blood vessels of CCRCC primary tumors can be used to predict, with high sensitivity and specificity, the patients that will respond to sunitinib therapy.
Molecular and Functional Analysis of Peripheral Lymphocytes in Churg Strauss Syndrome Reveals Several Monoclonal Expansions of CD8+ Cells with a Th1/Proinflammatory Profile
Authors: Monica Boita, Paola Circosta, Giuseppe Guida, Angela Rita Elia, Enrico Heffler, Massimo Geuna, Corrado Tarella, Giovanni Rolla, Alessandro Cignetti
Journal: Blood (2012)
Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia
Authors: Santi Suryani, Keith CS Sia, Lauryn Bracken, Hernan Carol, Kathryn Evans, Raushan Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Blood (2012)
TCT-20 Use of a Percutaneous Left Ventricular Assist Device for High Risk Percutaneous Coronary Interventions. Clinical Trial versus Real World Experience
Authors: Mauricio G. Cohen, Ray V. Matthews, Brij Maini, Simon Dixon, George W. Vetrovec, David H. Wohns, Igor F. Palacios, Jeffrey Popma, E. Magnus Ohman, Theodore Schreiber, William W. O'Neill
Journal: Journal of the American College of Cardiology (2015)
TCT-260 Combination of Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) Predicts Short-term and Long-term Clinical Outcomes in Patients with ST-segment Elevation Myocardial Infarction
Authors: Ki-Hyun Jeon, Ho-Jun Jang, Tae-Hoon Kim, Hyun Jong Lee, Jin Sik Park, Rak Kyong Choi, Young Jin Choi, Won Heum Shim, Young Moo Ro
Journal: Journal of the American College of Cardiology (2015)
Efficacy of Risk Adapted Cyclophosphamide, Thalidomide and Dexamethasone in Systemic AL Amyloidosis.
Authors: Ashutosh D. Wechalekar, Hugh J.B. Goodman, Julian D. Gillmore, Helen J. Lachmann, Mark Offer, Arthur R. Bradwell, Philip N. Hawkins
Journal: Blood (2005)
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells
Authors: Changchun Deng, Christine McIntosh, Richard Rodriguez, Peter Sportelli, Hari P. Miskin, Swaroop Vakkalanka, Srikant Viswanadha, Mark Lipstein, Owen A. O'Connor
Journal: Blood (2013)
THE RELATION OF THE SPLEEN TO BLOOD DESTRUCTION AND REGENERATION AND TO HEMOLYTIC JAUNDICE
Authors: J. H. Musser, Edward B. Krumbhaar
Journal: The Journal of Experimental Medicine (1913)

After splenectomy anemia usually develops quickly and reaches its height in from three to six weeks; then with gradual improvement the blood picture approaches the normal after about three to four months, with complete return to normal in five to ten months. Accompanying this is marked leucocytosis reaching its height in twenty-four hours but persisting to a slight degree for several months. Variations, however, may occur, in that the anemia may develop slowly and be of slight degree, or the reparative process may be delayed and up to ten months incomplete. The anemia is, however, inevitable, as is also, later, some degree of repair.
TCT-660 A Prospective Study of the Contemporary Role and Outcomes of Balloon Aortic Valvuloplasty: One Year Outcomes
Authors: Mani Arsalan, Molly Szerlip, Molly C. Mack, Giovanni Filardo, Rebeca J. Kim, Benjamin D. Pollock, Cynthia Rangel, J.M. DiMaio, Michael Mack, Elizabeth M. Holper
Journal: Journal of the American College of Cardiology (2015)